Pfizer says CFO Dave Denton will step down Aug. 15

Pfizer said its chief financial officer, Dave Denton, will step down effective August 15. The company framed the move as Denton pursuing a new professional opportunity, according to the news report.

The announcement sets up a leadership transition for one of the most central roles in a global pharmaceutical company, where the CFO oversees financial reporting, capital allocation, and investor communications as companies advance clinical programs and manage regulatory and commercial timelines.

Pfizer did not, in the cited report, provide details about who will assume the CFO responsibilities after August 15, nor did it outline whether a permanent successor has already been selected or will be named later. The company also did not disclose, in the report, any immediate changes to its near-term financial guidance practices.

For investors, the timing matters because CFO changes can coincide with periods of strategic execution, including major pipeline readouts and the ongoing management of costs and cash flow. While the report did not connect the step-down to a specific operational event, the change still raises the question of how Pfizer will manage continuity in its finance function during the transition.

Denton’s departure comes as the healthcare sector continues to navigate high regulatory scrutiny, uneven drug demand across therapeutic areas, and the financial pressures of research and development. In that environment, the CFO role is often a key point of contact for capital markets, particularly when companies face uncertainty around trial outcomes and product life-cycle decisions.

What is not clear from the report is the scope of any transition plan Pfizer may have in place, including whether there will be an interim CFO, how Denton’s responsibilities will be reassigned internally, and whether the company plans to provide further leadership updates on a set schedule.

The next items to watch are any follow-up Pfizer statements on succession, the appointment of an interim leader if needed, and how the company describes ongoing finance governance around its reporting cadence and investor communications as the August 15 date approaches.